We need to look at what the company has told us. First,

New Post Public Reply Private Reply Replies (0) Message Board
GaryM moxaman #12051
336
We need to look at what the company has told us. First, they showed two paths that their products will take, one for full drug approval, but the other as a cannabis based product where it can be legally sold. Second, they'll not be marketing the products they develop, so I think the company with the rights for a country or State will have some say as to when they'll market the products.

I would expect OWCP to have some control of when their partners can market the products, but only to the point where they know they're safe to do so, but they also could have to prove some degree of efficacy.

I know what they're doing is backwards to any other form of drug development, in fact they would never be permitted to market an unproven drug at all, but that's the cannabis market. Virtually nothing you can buy in a cannabis store is something that's been through full FDA approval, most have had little or no safety testing either, and that goes for the raw plant products to the oils, creams, candy, and goods sold in these stores.

Frankly, I'm uncertain if the Federal Govt. did change the category for cannabis if they couldn't then say the only products that can be sold must be FDA tested and approved. With that interpretation for legal cannabis I don't know that they wouldn't try to shut down cannabis stores and say approved products will be available in your local drug store.

I will hope the company clarifies when they intend to make the drug available to market, while I believe it could be after the safety trial, I also believe it's possible for them to say it will be after a Phase 2 where they'll be able to judge efficacy.

Of course their are other possibilities, Mediq had told some people they intended to run some tests themselves, if they were on schedule, they'd be done about now. No one seems to know what Mediq is doing, or if they're even still associated with OWCP. Could Michepro be doing something as well. We really don't know.

Let's look at the trial for Fibromyalgia. If that Phase 1 Trial is being done with patients who have the disease, it's possible that evidence of efficacy in Phase 1 is strong enough to go into that market with no further delay. The point is, we don't know, we're not even certain if that trial is being done with tablets, cream, or both products. I certainly hope we'll hear about this trial this week as well.

Their are a lot of potential catalysts which could send the stock up dramatically, the question is, what if anything will we learn about them this week.

Gary

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

The Future of Pharmaceutical Contract Packaging: Growth Insights

Updated Category News Views 74

Overview of the Pharmaceutical Contract Packaging Market The global market for pharmaceutical contract packaging is set to experience notable growth, propelled by advances in technology and increased investment in research and development. Estimates indicate a remarkable increase of USD 9.32 billion from 2024 to 2028, equating to a compound annual growth rate (CAGR) of...

Continue Reading
Palantir's CTO Highlights US Deterrence Challenges Ahead

Updated Category News Views 209

Palantir's CTO Discusses National Security Challenges Shyam Sankar, the Chief Technology Officer of the innovative data analytics and cybersecurity company Palantir Technologies Inc. (NASDAQ: PLTR), recently expressed serious concerns regarding America's fading deterrence capacity. While appearing on the New York Times podcast, he made it clear that the nation is no...

Continue Reading
Concerns Rise for Long-Term Investors of Super Micro Computer

Updated Category News Views 211

Investigation Launch: A Call to Action for Shareholders Bragar Eagel & Squire, P.C., a highly regarded law firm focused on shareholder rights, is launching an investigation into potential claims against Super Micro Computer, Inc. (NASDAQ: SMCI). This examination primarily targets the company’s conduct leading up to a class action lawsuit filed against it. The firm is...

Continue Reading
Children’s Place Reports Significant Results and Strategies Ahead

Updated Category News Views 283

Strong Performance in the Fourth Quarter The Children’s Place, Inc. (Nasdaq: PLCE), recognized as North America's leading children's specialty retailer, has reported remarkable progress in its financial performance for the fourth quarter. The company achieved net sales totaling $409 million for this quarter, along with a total of $1.386 billion for the entire fiscal...

Continue Reading
The Incredible Growth of Extra Space Storage Over Time

Updated Category News Views 391

Understanding Extra Space Storage's Historical Returns Extra Space Storage (NYSE: EXR) has significantly outperformed the market during the past 15 years, registering an impressive annualized return of 16.14%. This performance is not just a statistic; it represents a compound growth that can transform an initial investment. The Power of Compound Returns To illustrate...

Continue Reading